公开(公告)号：US11899024B2

公开(公告)日：2024-02-13

申请号：US16629000

申请日：2018-07-12

Applicant: Exosome Diagnostics, Inc.

Inventor： Mia Sher ,  Erez Eitan ,  Christine Coticchia ,  Johan Karl Olov Skog ,  Robert Kitchen ,  Seth Yu

IPC: G01N33/68 ,  G01N33/537 ,  C12N15/10

CPC classification number: G01N33/6896 ,  C12N15/1013 ,  G01N33/537 ,  G01N2333/705 ,  G01N2800/28

Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.

公开(公告)号：US11891664B2

公开(公告)日：2024-02-06

申请号：US16613298

申请日：2018-05-16

Applicant: Exosome Diagnostics, Inc. ,  The Brigham and Women's Hospital

Inventor： James Hurley ,  Christine Coticchia ,  Robert Kitchen ,  Vasisht Tadigotla ,  Johan Karl Olov Skog ,  Jamil Azzi

IPC: C12Q1/6883 ,  G01N1/28 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/158 ,  G01N1/28 ,  G01N33/6893 ,  G01N2800/245 ,  G01N2800/347

Abstract: The invention relates generally to the use of microvesicle biomarkers such as nucleic acids, including nucleic acid signatures, and/or proteins for assessing a kidney transplant rejection in a patient. The invention further relates to assessing, and/or to monitoring kidney transplant rejection in patients who have received a renal transplant.

公开(公告)号：US11345957B2

公开(公告)日：2022-05-31

申请号：US16631603

申请日：2018-07-18

Applicant: Exosome Diagnostics, Inc.

Inventor： Robert Kitchen ,  Michael Valentino ,  Johan Skog ,  Vasisht Tadigotla ,  Dalin Chan ,  Sudipto Chakrabortty ,  James Hurley

IPC: C12P19/34 ,  C12Q1/686 ,  C12Q1/6806 ,  C12Q1/6851 ,  C12Q1/6886

Abstract: The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).